Efficacy and safety of chemoradiotherapy plus immune checkpoint inhibitors for the treatment of locally advanced cervical cancer: a systematic review and meta-analysis
CORRECTION article
Corrigendum:Efficacy and safety of chemoradiotherapy plus immune checkpoint inhibitors for the treatment of locally advanced cervical cancer: a systematic review and meta-analysis
Provisionally accepted- 1.Department of radiation oncology, Shenzhen People’s Hospital, The Second clinical medical college, Jinan university, Guangdong, China, Shenzhen, China
• please read through all the templates before choosing• pick the most relevant text template(s) from the following page and delete all others.• edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below.• please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary• submit to Frontiers following the instructions on this page.When the original text contained incorrect information, to preserve the scientific record, please include that text when editing the below templates. There was a mistake in the Funding statement, an incorrect number was used. The correct number is "2015C03Bd051.". The publisher apologizes for this mistake.The original version of this article has been updated.In the published article, there was a mistake in the Affiliations of all authors. The Affiliations of all authors.was displayed as "Department of Radiation Oncology, Second Clinical Medicine Centre, Jinan University, Shenzhen, China.". The correct affiliations of all authorst is "Department of Radiation Oncology, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, Shenzhen, China.''In the published article, there was a mistake in the Affiliations of all authors. The Affiliations of all authors.was displayed as "Department of Radiation Oncology, Second Clinical Medicine Centre, Jinan University, Shenzhen, China."The correct affiliations of all authorst is "Department of Radiation Oncology, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, Shenzhen, China.''
Keywords: cervical cancer, chemotherapy, immune checkpoint inhibitors, Radiotherapy, randomized controlled trials
Received: 08 Nov 2024; Accepted: 14 Nov 2024.
Copyright: © 2024 Zhao, Ruan, Fang, Liu and Liao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Guixiang Liao, 1.Department of radiation oncology, Shenzhen People’s Hospital, The Second clinical medical college, Jinan university, Guangdong, China, Shenzhen, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.